isoproterenol has been researched along with exenatide in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Abo-Gresha, NM; Darwesh, AM; El-Azab, MF; El-Sayed, NM; Moustafa, YM | 1 |
1 review(s) available for isoproterenol and exenatide
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
1 other study(ies) available for isoproterenol and exenatide
| Article | Year |
|---|---|
Cardioprotective Mechanisms of Exenatide in Isoprenaline-induced Myocardial Infarction: Novel Effects on Myocardial α-Estrogen Receptor Expression and IGF-1/IGF-2 System.
Topics: Animals; Apoptosis; Cytoprotection; Disease Models, Animal; Estradiol; Estrogen Receptor alpha; Exenatide; Glucagon-Like Peptide-1 Receptor; Heart Rate; Insulin-Like Growth Factor I; Insulin-Like Growth Factor II; Isolated Heart Preparation; Isoproterenol; Male; Myocardial Infarction; Myocardium; Rats, Wistar; Receptor, IGF Type 1; Signal Transduction; Ventricular Function, Left | 2018 |